Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ming-Lung Yu

Showing results (451-460 of 527) with videos related to

Pageof 53
Sort By:
Journal of the Formosan Medical Association = Taiwan Yi Zhi|November 2, 2024
Addition of neutrophil-to-lymphocyte ratio to Pre-DAA FIB-4 does not increase prediction value for de novo liver complications in hepatitis CChun-Ming Hong, Tung-Hung Su, Shih-Jer Hsu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2024
Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular CarcinomaDaniel Q Huang, Joseph K Hoang, Rubayet Kamal, et al.
Hepatology International|December 5, 2020
HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohortYasuhito Tanaka, Eiichi Ogawa, Chung-Feng Huang, et al.
Scientific Reports|June 18, 2017
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C PatientsMei-Hsuan Lee, Chung-Feng Huang, Hsueh-Chou Lai, et al.
Kidney International Reports|August 11, 2020
2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference ReportPhilip Kam-Tao Li, Sunita Bavanandan, Rosmawati Mohamed, et al.
Hepatology International|August 30, 2019
Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C ConsortiumChung-Feng Huang, Etsuko Iio, Dae Won Jun, et al.
Hepatology (Baltimore, Md.)|May 15, 2023
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phaseDaniel Q Huang, Andrew Tran, Ming-Lun Yeh, et al.
Infectious Diseases and Therapy|April 9, 2025
Long-Term Hepatic and Extrahepatic Outcomes of Chronic Hepatitis C Patients After Sofosbuvir-Based Treatment (LONGHEAD Study)Chung-Feng Huang, Jeong Heo, Rong-Nan Chien, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 29, 2019
Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice ImplicationEiichi Ogawa, Hidenori Toyoda, Etsuko Iio, et al.
The American Journal of Gastroenterology|October 22, 2019
Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis BYao-Chun Hsu, Grace Lai-Hung Wong, Chien-Hung Chen, et al.
Pageof 53

Showing results (451-460 of 527) with videos related to

Sort By:
Pageof 53
Journal of the Formosan Medical Association = Taiwan Yi Zhi|November 2, 2024
Addition of neutrophil-to-lymphocyte ratio to Pre-DAA FIB-4 does not increase prediction value for de novo liver complications in hepatitis CChun-Ming Hong, Tung-Hung Su, Shih-Jer Hsu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2024
Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular CarcinomaDaniel Q Huang, Joseph K Hoang, Rubayet Kamal, et al.
Hepatology International|December 5, 2020
HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohortYasuhito Tanaka, Eiichi Ogawa, Chung-Feng Huang, et al.
Scientific Reports|June 18, 2017
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C PatientsMei-Hsuan Lee, Chung-Feng Huang, Hsueh-Chou Lai, et al.
Kidney International Reports|August 11, 2020
2018 Kidney Disease: Improving Global Outcomes (KDIGO) Hepatitis C in Chronic Kidney Disease Guideline Implementation: Asia Summit Conference ReportPhilip Kam-Tao Li, Sunita Bavanandan, Rosmawati Mohamed, et al.
Hepatology International|August 30, 2019
Direct-acting antivirals in East Asian hepatitis C patients: real-world experience from the REAL-C ConsortiumChung-Feng Huang, Etsuko Iio, Dae Won Jun, et al.
Hepatology (Baltimore, Md.)|May 15, 2023
Antiviral therapy substantially reduces HCC risk in patients with chronic hepatitis B infection in the indeterminate phaseDaniel Q Huang, Andrew Tran, Ming-Lun Yeh, et al.
Infectious Diseases and Therapy|April 9, 2025
Long-Term Hepatic and Extrahepatic Outcomes of Chronic Hepatitis C Patients After Sofosbuvir-Based Treatment (LONGHEAD Study)Chung-Feng Huang, Jeong Heo, Rong-Nan Chien, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 29, 2019
Hepatitis C Virus Cure Rates Are Reduced in Patients With Active but Not Inactive Hepatocellular Carcinoma: A Practice ImplicationEiichi Ogawa, Hidenori Toyoda, Etsuko Iio, et al.
The American Journal of Gastroenterology|October 22, 2019
Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis BYao-Chun Hsu, Grace Lai-Hung Wong, Chien-Hung Chen, et al.
Pageof 53